AMAG Pharmaceuticals, Takeda deal

The companies mutually terminated a 2010 deal granting the pharma exclusive rights to develop and commercialize Feraheme ferumoxytol in Europe, Canada, Turkey, the Commonwealth of Independent States and Asia-Pacific, excluding Japan, China and Taiwan. All rights reverted to AMAG, which now has worldwide rights to the IV iron replacement therapy. Takeda had marketed the drug as Feraheme in Canada and as Rienso in the EU to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). ...